<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02431052</url>
  </required_header>
  <id_info>
    <org_study_id>DRM01B-ACN02</org_study_id>
    <nct_id>NCT02431052</nct_id>
  </id_info>
  <brief_title>A Dose-ranging Study of DRM01 in Subjects With Acne Vulgaris</brief_title>
  <official_title>A Phase 2, Randomized, Double-blind, Vehicle-controlled, Dose-ranging Study of DRM01B Topical Gel in Subjects With Acne Vulgaris</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dermira, Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Dermira, Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objectives of this study are to assess the safety and efficacy DRM01 Topical Gel compared
      to vehicle in patients with acne vulgaris.
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date>April 2015</start_date>
  <completion_date type="Actual">April 2016</completion_date>
  <primary_completion_date type="Actual">April 2016</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Triple (Participant, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12</measure>
    <time_frame>Baseline and Week 12</time_frame>
    <description>Percentage of subjects who achieved ≥ 2-grade improvement and a grade of 0 or 1 in the investigator global assessment of acne (IGA) from baseline to Week 12
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
  </primary_outcome>
  <number_of_arms>5</number_of_arms>
  <enrollment type="Actual">420</enrollment>
  <condition>Acne Vulgaris</condition>
  <arm_group>
    <arm_group_label>Olumacostat Glasaretil Gel, Vehicle QD</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olumacostat Glasaretil Gel, Vehicle BID</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olumacostat Glasaretil Gel, 4.0% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olumacostat Glasaretil Gel, 7.5% QD</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Olumacostat Glasaretil Gel, 7.5% BID</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olumacostat Glasaretil</intervention_name>
    <arm_group_label>Olumacostat Glasaretil Gel, 4.0% QD</arm_group_label>
    <arm_group_label>Olumacostat Glasaretil Gel, 7.5% BID</arm_group_label>
    <arm_group_label>Olumacostat Glasaretil Gel, 7.5% QD</arm_group_label>
    <other_name>DRM01B</other_name>
  </intervention>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Vehicle</intervention_name>
    <arm_group_label>Olumacostat Glasaretil Gel, Vehicle BID</arm_group_label>
    <arm_group_label>Olumacostat Glasaretil Gel, Vehicle QD</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Signed informed consent.

          -  Male or non-pregnant, non-lactating females.

          -  Age ≥ 18 years.

          -  Clinical diagnosis of facial acne vulgaris defined as:

          -  At least 20 inflammatory lesions

          -  At least 20 non-inflammatory lesions

          -  Investigator Global Assessment of 3 or greater.

        Exclusion Criteria:

          -  Active cystic acne or acne conglobata, acne fulminans, and secondary acne.

          -  Two or more active nodulocystic lesions.

          -  Screening clinical chemistry or hematology laboratory value that is considered
             clinically significant, in the opinion of the Investigator.

          -  Abnormal findings on screening ECG, deemed clinically significant, by the
             Investigator.

          -  Subjects who are actively participating in an experimental therapy study or who have
             received experimental therapy within 30 days or 5 half-lives (whichever is longer) of
             the Baseline visit.

          -  Subjects who are a poor medical risk because of other systemic diseases or active
             uncontrolled infections, in the opinion of the investigator.

          -  Treatment with over-the-counter topical medications for the treatment of acne vulgaris
             including benzoyl peroxide, topical anti-inflammatory medications, corticosteroids,
             α-hydroxy/glycolic acid on the face within 2 weeks prior to Baseline.

          -  Treatment with systemic corticosteroids (use of intranasal and inhaled corticosteroids
             allowed for seasonal allergies and asthma) within 4 weeks prior to Baseline.

          -  Treatment with systemic antibiotics or systemic anti-acne drugs or systemic
             anti-inflammatory drugs within 4 weeks prior to Baseline.

          -  Prescription topical retinoid use on the face within 4 weeks of Baseline (e.g.,
             tretinoin, tazarotene, adapalene).

          -  Treatment with a new hormonal therapy or dose change to existing hormonal therapy
             within 12 weeks prior to Baseline. Dose and frequency of use of any hormonal therapy
             started more than 12 weeks prior to Baseline must remain unchanged throughout the
             study. Hormonal therapies include, but are not limited to, estrogenic and
             progestational agents such as birth control pills.

          -  Prior use of androgen receptor blockers (such as spironolactone or flutamide).

          -  Oral retinoid use (e.g., isotretinoin) within 12 months prior to Baseline or vitamin A
             supplements greater than 10,000 units/day within 6 months of Baseline.

          -  Facial procedures (chemical or laser peel, microdermabrasion, etc.) within the past 8
             weeks or during the study.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Beth Zib</last_name>
    <role>Study Director</role>
    <affiliation>Dermira, Inc.</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Coastal Clinical Research, Inc.</name>
      <address>
        <city>Mobile</city>
        <state>Alabama</state>
        <zip>36608</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>T. Joseph Raoof, MD, Inc.</name>
      <address>
        <city>Encino</city>
        <state>California</state>
        <zip>94136</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>University Clinical Trials, Inc.</name>
      <address>
        <city>San Diego</city>
        <state>California</state>
        <zip>92123</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Tory Sullivan MD PA</name>
      <address>
        <city>North Miami Beach</city>
        <state>Florida</state>
        <zip>33162</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - US, LLC</name>
      <address>
        <city>Sanford</city>
        <state>Florida</state>
        <zip>32771</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>MOORE Clinical Research, Inc.</name>
      <address>
        <city>Tampa</city>
        <state>Florida</state>
        <zip>33609</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Visions Clinical Research</name>
      <address>
        <city>Wellington</city>
        <state>Florida</state>
        <zip>33414</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, PLLC</name>
      <address>
        <city>Louisville</city>
        <state>Kentucky</state>
        <zip>40217</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lawrence J. Green, MD, LLC</name>
      <address>
        <city>Rockville</city>
        <state>Maryland</state>
        <zip>20850</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Michigan Center for Skin Care Research</name>
      <address>
        <city>Clinton Township</city>
        <state>Michigan</state>
        <zip>48038</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Henry Ford Health System</name>
      <address>
        <city>Detroit</city>
        <state>Michigan</state>
        <zip>48202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Minnesota Clinical Study Center</name>
      <address>
        <city>Fridley</city>
        <state>Minnesota</state>
        <zip>55432</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Las Vegas Dermatology</name>
      <address>
        <city>Las Vegas</city>
        <state>Nevada</state>
        <zip>89144</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Academic Dermatology Associates</name>
      <address>
        <city>Albuquerque</city>
        <state>New Mexico</state>
        <zip>87106</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Skin Search of Rochester, Inc.</name>
      <address>
        <city>Rochester</city>
        <state>New York</state>
        <zip>14623</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Consulting Services</name>
      <address>
        <city>High Point</city>
        <state>North Carolina</state>
        <zip>27262</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Skin Wellness Center</name>
      <address>
        <city>Knoxville</city>
        <state>Tennessee</state>
        <zip>37922</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>International Clinical Research - Tennessee LLC</name>
      <address>
        <city>Murfreesboro</city>
        <state>Tennessee</state>
        <zip>37130</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>DermResearch, Inc</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78759</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>J&amp;S Studies, Inc.</name>
      <address>
        <city>College Station</city>
        <state>Texas</state>
        <zip>77845</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Center for Clinical Studies, LTD. LLP</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77004</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce &amp; Associates, PA. The Center for Skin Research</name>
      <address>
        <city>Houston</city>
        <state>Texas</state>
        <zip>77056</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Suzanne Bruce &amp; Associates, PA. The Center for Skin Research</name>
      <address>
        <city>Katy</city>
        <state>Texas</state>
        <zip>77494</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Austin Institute for Clinical Research</name>
      <address>
        <city>Pflugerville</city>
        <state>Texas</state>
        <zip>78660</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Progressive Clinical Research, PA</name>
      <address>
        <city>San Antonio</city>
        <state>Texas</state>
        <zip>78229</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Dermatology Research Center, Inc.</name>
      <address>
        <city>Salt Lake City</city>
        <state>Utah</state>
        <zip>84117</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Education &amp; Research Foundation, Inc.</name>
      <address>
        <city>Lynchburg</city>
        <state>Virginia</state>
        <zip>24501</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Premier Clinical Research</name>
      <address>
        <city>Spokane</city>
        <state>Washington</state>
        <zip>99202</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kirk Barber Research</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2G1B1</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Enverus Medical Research</name>
      <address>
        <city>Surrey</city>
        <state>British Columbia</state>
        <zip>V3V0C6</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Lynderm Research</name>
      <address>
        <city>Markham</city>
        <state>Ontario</state>
        <zip>L3P1X2</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Windsor Clinical Research, Inc.</name>
      <address>
        <city>Windsor</city>
        <state>Ontario</state>
        <zip>N8W 5L7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Innovaderm Research Inc.</name>
      <address>
        <city>Montreal</city>
        <state>Quebec</state>
        <zip>H2K 4L5</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Centre de Recherche Dermetologique du Quebec Metropolitain (CRDQ)</name>
      <address>
        <city>Quebec</city>
        <zip>G1V 4X7</zip>
        <country>Canada</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Canada</country>
    <country>United States</country>
  </location_countries>
  <verification_date>February 2019</verification_date>
  <study_first_submitted>April 27, 2015</study_first_submitted>
  <study_first_submitted_qc>April 29, 2015</study_first_submitted_qc>
  <study_first_posted type="Estimate">April 30, 2015</study_first_posted>
  <results_first_submitted>January 31, 2019</results_first_submitted>
  <results_first_submitted_qc>February 25, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 26, 2019</results_first_posted>
  <disposition_first_submitted>January 30, 2018</disposition_first_submitted>
  <disposition_first_submitted_qc>January 30, 2018</disposition_first_submitted_qc>
  <disposition_first_posted type="Actual">February 1, 2018</disposition_first_posted>
  <last_update_submitted>February 25, 2019</last_update_submitted>
  <last_update_submitted_qc>February 25, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 26, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acne Vulgaris</mesh_term>
  </condition_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Olumacostat Glasaretil Gel, Vehicle QD</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="P2">
          <title>Olumacostat Glasaretil Gel, Vehicle BID</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="P3">
          <title>Olumacostat Glasaretil Gel, 4.0% QD</title>
          <description>Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="P4">
          <title>Olumacostat Glasaretil Gel, 7.5% QD</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="P5">
          <title>Olumacostat Glasaretil Gel, 7.5% BID</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="53"/>
                <participants group_id="P2" count="50"/>
                <participants group_id="P3" count="106"/>
                <participants group_id="P4" count="110"/>
                <participants group_id="P5" count="101"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="42"/>
                <participants group_id="P2" count="46"/>
                <participants group_id="P3" count="94"/>
                <participants group_id="P4" count="94"/>
                <participants group_id="P5" count="86"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="11"/>
                <participants group_id="P2" count="4"/>
                <participants group_id="P3" count="12"/>
                <participants group_id="P4" count="16"/>
                <participants group_id="P5" count="15"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <population>Intent-to-Treat</population>
      <group_list>
        <group group_id="B1">
          <title>Olumacostat Glasaretil Gel, Vehicle QD</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="B2">
          <title>Olumacostat Glasaretil Gel, Vehicle BID</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="B3">
          <title>Olumacostat Glasaretil Gel, 4.0% QD</title>
          <description>Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="B4">
          <title>Olumacostat Glasaretil Gel, 7.5% QD</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="B5">
          <title>Olumacostat Glasaretil Gel, 7.5% BID</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="B6">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="52"/>
            <count group_id="B2" value="50"/>
            <count group_id="B3" value="106"/>
            <count group_id="B4" value="110"/>
            <count group_id="B5" value="101"/>
            <count group_id="B6" value="419"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="6"/>
                    <measurement group_id="B2" value="3"/>
                    <measurement group_id="B3" value="10"/>
                    <measurement group_id="B4" value="15"/>
                    <measurement group_id="B5" value="14"/>
                    <measurement group_id="B6" value="48"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="46"/>
                    <measurement group_id="B2" value="47"/>
                    <measurement group_id="B3" value="96"/>
                    <measurement group_id="B4" value="95"/>
                    <measurement group_id="B5" value="87"/>
                    <measurement group_id="B6" value="371"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>Years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="26.8" spread="7.65"/>
                    <measurement group_id="B2" value="26.7" spread="7.04"/>
                    <measurement group_id="B3" value="27" spread="8.13"/>
                    <measurement group_id="B4" value="26.4" spread="7.96"/>
                    <measurement group_id="B5" value="25.9" spread="8.26"/>
                    <measurement group_id="B6" value="26.5" spread="7.90"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="39"/>
                    <measurement group_id="B3" value="77"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="79"/>
                    <measurement group_id="B6" value="316"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="14"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="29"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="22"/>
                    <measurement group_id="B6" value="103"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Ethnicity (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="9"/>
                    <measurement group_id="B3" value="24"/>
                    <measurement group_id="B4" value="27"/>
                    <measurement group_id="B5" value="32"/>
                    <measurement group_id="B6" value="104"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Not Hispanic or Latino</title>
                  <measurement_list>
                    <measurement group_id="B1" value="38"/>
                    <measurement group_id="B2" value="41"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="83"/>
                    <measurement group_id="B5" value="68"/>
                    <measurement group_id="B6" value="311"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="1"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Race (NIH/OMB)</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>American Indian or Alaska Native</title>
                  <measurement_list>
                    <measurement group_id="B1" value="2"/>
                    <measurement group_id="B2" value="1"/>
                    <measurement group_id="B3" value="1"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="5"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Asian</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="4"/>
                    <measurement group_id="B4" value="6"/>
                    <measurement group_id="B5" value="6"/>
                    <measurement group_id="B6" value="19"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Native Hawaiian or Other Pacific Islander</title>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="2"/>
                    <measurement group_id="B4" value="1"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="4"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Black or African American</title>
                  <measurement_list>
                    <measurement group_id="B1" value="16"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="27"/>
                    <measurement group_id="B4" value="24"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="99"/>
                  </measurement_list>
                </category>
                <category>
                  <title>White</title>
                  <measurement_list>
                    <measurement group_id="B1" value="28"/>
                    <measurement group_id="B2" value="33"/>
                    <measurement group_id="B3" value="69"/>
                    <measurement group_id="B4" value="75"/>
                    <measurement group_id="B5" value="72"/>
                    <measurement group_id="B6" value="277"/>
                  </measurement_list>
                </category>
                <category>
                  <title>More than one race</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="3"/>
                    <measurement group_id="B4" value="3"/>
                    <measurement group_id="B5" value="3"/>
                    <measurement group_id="B6" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Unknown or Not Reported</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                    <measurement group_id="B4" value="0"/>
                    <measurement group_id="B5" value="0"/>
                    <measurement group_id="B6" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Canada</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="11"/>
                    <measurement group_id="B2" value="12"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="25"/>
                    <measurement group_id="B5" value="24"/>
                    <measurement group_id="B6" value="97"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="41"/>
                    <measurement group_id="B2" value="38"/>
                    <measurement group_id="B3" value="81"/>
                    <measurement group_id="B4" value="85"/>
                    <measurement group_id="B5" value="77"/>
                    <measurement group_id="B6" value="322"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Fitzpatrick Skin Type</title>
          <description>Fitzpatrick Skin Type is a scale to numerically classify skin color, defined by the response to ultraviolet (UV) light with the following categories:
Type I Burns easily, rarely tans Type II Burns easily, tans minimally Type III Burns moderately, tans gradually Type IV Burns minimally, tans well Type V Rarely burns, tans profusely Type VI Never burns, deeply pigmented</description>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <title>Type I</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="1"/>
                    <measurement group_id="B2" value="2"/>
                    <measurement group_id="B3" value="7"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="5"/>
                    <measurement group_id="B6" value="27"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type II</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="17"/>
                    <measurement group_id="B4" value="23"/>
                    <measurement group_id="B5" value="20"/>
                    <measurement group_id="B6" value="76"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type III</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="12"/>
                    <measurement group_id="B2" value="17"/>
                    <measurement group_id="B3" value="26"/>
                    <measurement group_id="B4" value="28"/>
                    <measurement group_id="B5" value="30"/>
                    <measurement group_id="B6" value="113"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type IV</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="15"/>
                    <measurement group_id="B2" value="13"/>
                    <measurement group_id="B3" value="25"/>
                    <measurement group_id="B4" value="22"/>
                    <measurement group_id="B5" value="23"/>
                    <measurement group_id="B6" value="98"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type V</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="8"/>
                    <measurement group_id="B2" value="4"/>
                    <measurement group_id="B3" value="9"/>
                    <measurement group_id="B4" value="12"/>
                    <measurement group_id="B5" value="13"/>
                    <measurement group_id="B6" value="46"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Type VI</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="7"/>
                    <measurement group_id="B2" value="7"/>
                    <measurement group_id="B3" value="22"/>
                    <measurement group_id="B4" value="13"/>
                    <measurement group_id="B5" value="10"/>
                    <measurement group_id="B6" value="59"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12</title>
        <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, Vehicle QD</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks
Olumacostat Glasaretil</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle BID</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks
Olumacostat Glasaretil</description>
          </group>
          <group group_id="O3">
            <title>Olumacostat Glasaretil Gel, 4.0% QD</title>
            <description>Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks
Olumacostat Glasaretil</description>
          </group>
          <group group_id="O4">
            <title>Olumacostat Glasaretil Gel, 7.5% QD</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks
Vehicle</description>
          </group>
          <group group_id="O5">
            <title>Olumacostat Glasaretil Gel, 7.5% BID</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks
Vehicle</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Acne Lesion Counts (Inflammatory) From Baseline to Week 12</title>
          <description>Mean absolute change in acne lesion counts (inflammatory) from baseline to Week 12</description>
          <population>Intent-to-Treat</population>
          <units>Lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-10.5" spread="9.79"/>
                    <measurement group_id="O2" value="-11.0" spread="9.04"/>
                    <measurement group_id="O3" value="-14.6" spread="9.22"/>
                    <measurement group_id="O4" value="-14.5" spread="9.49"/>
                    <measurement group_id="O5" value="-15.0" spread="9.35"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0006</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>ANCOVA with factors of treatment group (combined vehicle as one group) and baseline count as covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12</title>
        <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-To-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, Vehicle QD</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle BID</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olumacostat Glasaretil Gel, 4.0% QD</title>
            <description>Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Olumacostat Glasaretil Gel, 7.5% QD</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Olumacostat Glasaretil Gel, 7.5% BID</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Mean Absolute Change in Acne Lesion Counts (Non-inflammatory) From Baseline to Week 12</title>
          <description>Mean absolute change in acne lesion counts (non-inflammatory) from baseline to Week 12</description>
          <population>Intent-To-Treat</population>
          <units>Lesions</units>
          <param>Least Squares Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="-9.3" spread="15.62"/>
                    <measurement group_id="O2" value="-9.3" spread="15.07"/>
                    <measurement group_id="O3" value="-15.3" spread="15.17"/>
                    <measurement group_id="O4" value="-13.4" spread="15.42"/>
                    <measurement group_id="O5" value="-17.5" spread="15.15"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0002</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>ANCOVA with factors of treatment group (combined vehicle as one group) and baseline count as covariate.</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12</title>
        <description>Percentage of subjects who achieved ≥ 2-grade improvement and a grade of 0 or 1 in the investigator global assessment of acne (IGA) from baseline to Week 12
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
        <time_frame>Baseline and Week 12</time_frame>
        <population>Intent-to-Treat</population>
        <group_list>
          <group group_id="O1">
            <title>Olumacostat Glasaretil Gel, Vehicle QD</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O2">
            <title>Olumacostat Glasaretil Gel, Vehicle BID</title>
            <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
          </group>
          <group group_id="O3">
            <title>Olumacostat Glasaretil Gel, 4.0% QD</title>
            <description>Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O4">
            <title>Olumacostat Glasaretil Gel, 7.5% QD</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks</description>
          </group>
          <group group_id="O5">
            <title>Olumacostat Glasaretil Gel, 7.5% BID</title>
            <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Percentage of Subjects Who Achieved ≥ 2-grade Improvement and a Grade of 0 or 1 in the Investigator Global Assessment of Acne (IGA) From Baseline to Week 12</title>
          <description>Percentage of subjects who achieved ≥ 2-grade improvement and a grade of 0 or 1 in the investigator global assessment of acne (IGA) from baseline to Week 12
Scoring Criteria for Investigator Global Assessment 0 - Clear skin with no inflammatory or noninflammatory lesions
- Almost clear; rare noninflammatory lesions with no more than one small inflammatory lesion
- Mild severity; greater than Grade 1; some noninflammatory lesions with no more than a few inflammatory lesions (papules/pustules only, no nodular lesions)
- Moderate severity; greater than Grade 2; up to many noninflammatory lesions and may have some inflammatory lesions, but no more than one small nodular lesion
- Severe; greater than Grade 3; up to many noninflammatory and inflammatory lesions, but no more than a few nodular lesions</description>
          <population>Intent-to-Treat</population>
          <units>Participants</units>
          <param>Count of Participants</param>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="52"/>
                <count group_id="O2" value="50"/>
                <count group_id="O3" value="106"/>
                <count group_id="O4" value="110"/>
                <count group_id="O5" value="101"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <title>Success</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="4"/>
                    <measurement group_id="O2" value="6"/>
                    <measurement group_id="O3" value="23"/>
                    <measurement group_id="O4" value="21"/>
                    <measurement group_id="O5" value="26"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
            <class>
              <title>Failure</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="48"/>
                    <measurement group_id="O2" value="44"/>
                    <measurement group_id="O3" value="83"/>
                    <measurement group_id="O4" value="89"/>
                    <measurement group_id="O5" value="75"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
              <group_id>O3</group_id>
              <group_id>O4</group_id>
              <group_id>O5</group_id>
            </group_id_list>
            <non_inferiority_type>Other</non_inferiority_type>
            <p_value>0.0055</p_value>
            <method>Cochran-Mantel-Haenszel</method>
            <method_desc>Cochran-Mantel-Haenszel test (vehicle treatment groups included as single combined treatment group).</method_desc>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <time_frame>Baseline to Week 12</time_frame>
      <desc>The Total Participants at risk are based on the Safety Population defined as Participants who were randomized and received at least one confirmed dose of study drug.</desc>
      <group_list>
        <group group_id="E1">
          <title>Olumacostat Glasaretil Gel, Vehicle QD</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="E2">
          <title>Olumacostat Glasaretil Gel, Vehicle BID</title>
          <description>Olumacostat Glasaretil Gel, Vehicle, applied twice daily to the face for 12 weeks</description>
        </group>
        <group group_id="E3">
          <title>Olumacostat Glasaretil Gel, 4.0% QD</title>
          <description>Olumacostat Glasaretil Gel, 4.0%, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="E4">
          <title>Olumacostat Glasaretil Gel, 7.5% QD</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied once daily to the face for 12 weeks</description>
        </group>
        <group group_id="E5">
          <title>Olumacostat Glasaretil Gel, 7.5% BID</title>
          <description>Olumacostat Glasaretil Gel, 7.5%, applied twice daily to the face for 12 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="0" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Neoplasms benign, malignant and unspecified (incl cysts and polyps)</title>
            <event_list>
              <event>
                <sub_title>Uterine Leiomyoma</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="0" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="1" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="0" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>Infections and infestations</title>
            <event_list>
              <event>
                <sub_title>Nasopharyngitis</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="52"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="50"/>
                <counts group_id="E3" subjects_affected="4" subjects_at_risk="106"/>
                <counts group_id="E4" subjects_affected="6" subjects_at_risk="109"/>
                <counts group_id="E5" subjects_affected="7" subjects_at_risk="101"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There IS an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Reema Singh</name_or_title>
      <organization>Dermira, Inc.</organization>
      <phone>650-421-2951</phone>
      <email>reema.singh@dermira.com</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

